Providence Cancer Institute

What Providence Cancer Institute does

Providence Cancer Institute is a not-for-profit cancer care and research division of Providence St. Joseph Health, headquartered in Portland, Oregon, with additional clinical sites across Oregon and the broader Western U.S. It serves cancer patients across multiple tumor types (head and neck, breast, colorectal, pancreatic, multiple myeloma, lymphoma, melanoma, and others) through a comprehensive care model spanning prevention, diagnosis, treatment, clinical trials, and survivorship. The institute offers immunotherapy, chemotherapy, radiation therapy, targeted therapy, surgery, and a prevention program (Prevention4ME) that combines genomic risk with family history and lifestyle factors for early risk stratification.

Research and technological differentiation are anchored by the Earle A. Chiles Research Institute, which runs a portfolio of early-phase, investigator-initiated, cooperative group, and industry-sponsored clinical trials — described as one of the largest early-phase portfolios on the West Coast. The institute has developed proprietary AI capabilities in partnership with Microsoft Research and University of Washington, including GigaTIME (a pathology model for tumor microenvironment analysis, published in Cell) and TRIALSCOPE (a framework for predicting trial outcomes from real-world evidence and clinical genomics). It is also developing in-house novel therapeutics such as the M3T01 Fas ligand inhibitor and runs trials for externally developed agents including KLN-1010 in-vivo CAR T gene therapy and the EP0031 selective RET inhibitor.

Revenue is generated through patient care services (reimbursed via insurance, Medicare, Medicaid, and patient payments), industry- and government-sponsored clinical research, and philanthropy — with approximately 70% of research funded by donor support. The customer base is highly diversified across individual patients and referring physicians, with no apparent revenue concentration; institutional payer and research-sponsor relationships provide additional revenue streams. Awards include the NCORP Gold Certificate of Excellence, Newsweek Best-in-State Hospitals 2026, and 2025 SITC Champion awards to three researchers.

Name

Providence Cancer Institute

Legal name

Providence St. Joseph Health

Website

https://providence.org

Company type

Private

Founded year

1850

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Providence Cancer Institute is a not-for-profit cancer care and research division of Providence St. Joseph Health, based in Portland, Oregon, delivering comprehensive oncology care, clinical trials, and immuno-oncology research across the Western U.S.

Ownership category

akta.pro rank

Product category

Oncology and Cancer Care Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Cancer care services
• Oncology treatment
• Clinical trials
• Immuno-oncology research
• Cancer prevention programs

Headquarters

HQ city

Portland

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Patient Care Services: Healthcare services including cancer treatment, surgery, chemotherapy, radiation therapy, immunotherapy, and other medical services provided to patients. Revenue generated through insurance reimbursements, Medicare, Medicaid, and patient payments.
2. Clinical Research: Revenue from conducting clinical trials for pharmaceutical and biotech companies, NCI-sponsored research, and investigator-initiated studies. Includes industry-sponsored trials and government grants.
3. Philanthropy and Donations: Donor support that fuels approximately 70% of groundbreaking research at Providence Cancer Institute, including clinical trial programs. Includes contributions from individuals, foundations, and charitable organizations.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Providence Cancer Institute delivers comprehensive cancer care spanning diagnosis, treatment (chemotherapy, radiation therapy, immunotherapy, targeted therapy, surgery), clinical trials, and survivorship support. It operates the Earle A. Chiles Research Institute for immuno-oncology research and early-phase clinical trials, supported by digital tools including the Providence App and MyChart portal. Services are delivered through a network of hospitals, oncology clinics, and community locations across Oregon, with philanthropic support funding approximately 70% of its research.

Product overview

Providence Cancer Institute is a comprehensive cancer care network offering a unified platform of clinical services, research programs, and digital health tools. The core offering centers on Providence Cancer Institute, a leading cancer care provider in Oregon and global leader in immuno-oncology, supported by the Earle A. Chiles Research Institute for advanced research. The institute provides specialized programs including Colorectal Cancer Program, Gynecologic Oncology Program, and Prevention4ME for risk assessment. Digital infrastructure includes the Providence App for patient engagement and MyChart portal for health records access. Treatment services are augmented by extensive clinical trial programs covering early-phase, investigator-initiated, and industry-sponsored trials across multiple therapy areas including immunotherapy, gene therapy, and targeted therapies.

Differentiator

Problem solved

Functional benefit

Brands

• Earle A. Chiles Research Institute: Research division of Providence Cancer Institute of Oregon, specializing in immuno-oncology research, genomic sequencing, and adoptive cellular therapies.

Products and services

• Providence Cancer Institute Comprehensive cancer care center offering cancer treatment, clinical trials, genomic sequencing, and cellular therapies across multiple locations in Oregon. A leading provider of cancer care in Oregon and a global leader in immuno-oncology.
• Earle A. Chiles Research Institute Research division of Providence Cancer Institute of Oregon providing state-of-the-art genomic sequencing, adoptive cellular therapies, and a robust clinical research portfolio comprising early phase, investigator-initiated, cooperative group, and industry-sponsored trials.
• Colorectal Cancer Program Comprehensive program for colorectal cancer screening, prevention, and treatment offering information on screening and prevention.
• Providence Oncology and Hematology Care Clinic Provides oncology and hematology care services with access to clinical trials and advanced treatments.
• Providence Gynecologic Oncology Program and Clinic Provides specialized care for gynecologic cancers with access to clinical trials and advanced treatments.
• Prevention4ME A groundbreaking program using genomic risk, family history, and lifestyle factors to help patients identify or lower their cancer risk early.
• Providence App Mobile application enabling patients to schedule appointments, conduct virtual visits, receive updates from care team, view health records, and access medical information on-the-go.
• MyChart Patient portal providing up-to-date information on appointments, medications, health conditions, labs, studies, after-visit summaries, and clinical notes in real time.
• Virtual Care Virtual visit services enabling patients to see healthcare providers through online video and phone appointments without visiting a doctor's office.

Quantifiable outcome

• 83% of head and neck cancer patients avoided post-operative chemoradiation with neoadjuvant immunotherapy + focused radiation protocol
• +5 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• National Institutes of Health (NIH)coreStrategic or Co-development Partner · 12 May 2026NIH awarded $3.4 million five-year grant (R01CA301042) to Earle A. Chiles Research Institute for head and neck cancer research studying neoadjuvant immunotherapy plus focused radiation protocol. Federal funding finances approximately 81% of the project.
• University of California San DiegominorStrategic or Co-development Partner · 12 May 2026Collaborative research on head and neck cancer showing that intact draining lymph nodes are essential for response to immunotherapy. Studies conducted at both EACRI and in collaboration with UC San Diego.
• University of California Los Angeles (UCLA)minorStrategic or Co-development Partner · 12 January 2026Collaborative study on building trust with diverse communities for biospecimen research participation. Study conducted between 2022-2024 led by Providence in collaboration with UCLA and Massachusetts General Hospital.
• Massachusetts General HospitalminorStrategic or Co-development Partner · 12 January 2026Collaborative study on building trust with diverse communities for biospecimen research participation. Research aimed at addressing health disparities and improving outcomes for populations underrepresented in medical studies.
• Kelonia TherapeuticscoreStrategic or Co-development Partner · 1 January 2026Clinical trial partnership for KLN-1010 gene therapy for relapsed/refractory multiple myeloma. Providence Cancer Institute is the only site outside of Australia enrolling patients in the inMMyCAR phase I study. FDA cleared the therapy in January 2026 following phase I data presentation at ASH.
• Providence Saint John's Cancer InstitutecoreStrategic or Co-development Partner · 12 December 2025Partnership on early onset colorectal cancer research study. Providence's Health Research Accelerator partnered with Providence Saint John's Cancer Institute in Santa Monica, California on the study published in Cancer Prevention Research.
• Microsoft ResearchcoreStrategic or Co-development Partner · 1 January 2025Partnership with Microsoft Research and University of Washington to develop GigaTIME AI-powered pathology model for tumor microenvironment analysis and TRIALSCOPE AI framework for clinical trial optimization. Both projects were published in major scientific journals (Cell, presented at conferences).
• University of WashingtoncoreStrategic or Co-development Partner · 1 January 2025Collaborative research partnership in AI development for cancer diagnostics and treatment optimization. Joint development of GigaTIME and TRIALSCOPE AI frameworks with Microsoft Research and Providence researchers.
• ECOG-ACRIN Cancer Research GroupcoreStrategic or Co-development Partner · 1 January 2025Providence participates in this international scientific organization and NCI National Clinical Trials Network group. Dr. Natasha Edwin serves as community co-chair of the ECOG-ACRIN Myeloma Committee, shaping trial design for community settings.
• Institute for Systems BiologyminorStrategic or Co-development Partner · 1 January 2025Affiliated research organization where Mary Brunkow, Ph.D. conducted Nobel Prize-winning immune system research that has impacted Providence's own research programs.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Roswell Park Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center with a strong research portfolio in immunotherapy and clinical trials, comparable to Providence in its blend of specialty care delivery and translational research.
• MD Anderson Cancer Center: One of the original NCI-designated Comprehensive Cancer Centers, MD Anderson offers oncology care, research, and clinical trials at a scale that Providence Cancer Institute competes with for complex cancer cases, principal investigators, and federally funded research.
• Fred Hutchinson Cancer Center: Seattle-based NCI-designated Comprehensive Cancer Center focused on immuno-oncology, bone marrow transplantation, and clinical research, and a direct geographic peer in the Pacific Northwest competing for patients, principal investigators, and trial sponsorships.
• Mayo Clinic Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center within a large nonprofit health system, similar in structure to Providence Cancer Institute as part of Providence St. Joseph Health, and a peer for specialty oncology referrals, clinical trials, and research output.
• City of Hope Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center with deep expertise in immunotherapy, hematology, and early-phase clinical trials, mirroring Providence's focus on immuno-oncology and serving as a competitor for trial sponsors and complex cancer patients.
• Memorial Sloan Kettering Cancer Center: Premier NCI-designated cancer center providing specialty oncology care, translational research, and one of the largest U.S. clinical trial portfolios, competing with Providence for patients, talent, and industry-sponsored trials.
• Providence Saint John's Cancer Institute: Sister cancer institute within the same Providence St. Joseph Health system, partnering with Providence Cancer Institute on early onset colorectal cancer research and offering comparable oncology programs, clinical trials, and immuno-oncology research.
• Stanford Cancer Institute: NCI-designated cancer center at Stanford Medicine with strengths in immuno-oncology, genomics, and early-phase trials, comparable to Providence in academic research output and trial sophistication.
• Dana-Farber Cancer Institute: Harvard-affiliated NCI-designated Comprehensive Cancer Center renowned for translational research, early-phase trials, and immuno-oncology, comparable to Providence in its integration of research and clinical care delivery.
• UCSF Helen Diller Family Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center within an academic health system, with active research in immunotherapy and clinical trials, and an overlapping geographic and academic peer set with Providence Cancer Institute.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/providence
• YouTubeyoutube.com/channel/UCCJ8wEkiHBHkVD8Jb7sbIBg/featured
• Facebookfacebook.com/providence
• LinkedInlinkedin.com/company/providencecancerinstitute
• Instagraminstagram.com/providencehealthsystem

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Providence Cancer Institute